TD Cowen raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps a Hold rating on the shares. The firm previewed its Q4 results and updated estimates to reflect that Sanofi Q4 reported Nuvaxovid sales of EUR 9MM; and license agreement with Pfizer which includes $30MM upfront payment and high MSD royalties on Pfizer (PFE) products containing Matrix-M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Is NVAX a Buy, Before Earnings?
- Options Volatility and Implied Earnings Moves This Week, February 23 – February 26, 2026
- Novavax Soars as Traders Bet Big on Vaccine Future
- Novavax call volume above normal and directionally bullish
- Novavax: Execution Risks, Long-Dated Cash Flows, and COVID Market Headwinds Undermine Profitability Outlook